J-ALEX: alectinib versus crizotinib in ALK-positive lung cancer

被引：6
|
作者：
Gainor, Justin F. [1 ]
Shaw, Alice T. [1 ]
机构：
[1] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA
来源：
LANCET | 2017年 / 390卷 / 10089期
关键词：
PROGRESSION-FREE; OPEN-LABEL; CHEMOTHERAPY; CERITINIB; SURVIVAL;
D O I：
10.1016/S0140-6736(17)31074-7
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：3 / 4
页数：2
相关论文
共 50 条
  • [41] An update on Alectinib: a first line treatment for ALK-positive advanced lung cancer
    Zhou, Yourong
    Yin, Yiming
    Xu, Jiangxin
    Xu, Zhifei
    Yang, Bo
    He, Qiaojun
    Luo, Peihua
    Yan, Hao
    Yang, Xiaochun
    EXPERT OPINION ON PHARMACOTHERAPY, 2023, 24 (12) : 1361 - 1373
  • [42] Alectinib in resected ALK-positive non-small-cell lung cancer
    Gourmet, Anais
    Ferrari, Victoria
    BULLETIN DU CANCER, 2024, 111 (10) : 905 - 906
  • [43] Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer
    Wu, Yi-Long
    Dziadziuszko, Rafal
    Ahn, Jin Seok
    Barlesi, Fabrice
    Nishio, Makoto
    Lee, Dae Ho
    Lee, Jong-Seok
    Zhong, Wenzhao
    Horinouchi, Hidehito
    Mao, Weimin
    Hochmair, Maximilian
    de Marinis, Filippo
    Migliorino, M. Rita
    Bondarenko, Igor
    Lu, Shun
    Wang, Qun
    Ochi Lohmann, Tania
    Xu, Tingting
    Cardona, Andres
    Ruf, Thorsten
    Noe, Johannes
    Solomon, Benjamin J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (14): : 1265 - 1276
  • [44] Alectinib for treatment of ALK-positive non-small-cell lung cancer
    Avrillon, Virginie
    Perol, Maurice
    FUTURE ONCOLOGY, 2017, 13 (04) : 321 - 335
  • [45] Alectinib for advanced ALK-positive non-small-cell lung cancer
    Ly, Ashley C.
    Olin, Jacqueline L.
    Smith, Morgan B.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2018, 75 (08) : 515 - 522
  • [46] Exposure-response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer
    Morcos, Peter N.
    Nueesch, Eveline
    Jaminion, Felix
    Guerini, Elena
    Hsu, Joy C.
    Bordogna, Walter
    Balas, Bogdana
    Mercier, Francois
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (01) : 129 - 138
  • [47] Ceritinib versus chemotherapy in ALK-positive lung cancer
    Marshall, Hilary
    LANCET RESPIRATORY MEDICINE, 2016, 4 (12): : 952 - 953
  • [48] Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer (vol 368, pg 2385, 2013)
    不详
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (16): : 1582 - 1582
  • [49] First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer
    Shaw, Alice T.
    Bauer, Todd M.
    de Marinis, Filippo
    Felip, Enriqueta
    Goto, Yasushi
    Liu, Geoffrey
    Mazieres, Julien
    Kim, Dong-Wan
    Mok, Tony
    Polli, Anna
    Thurm, Holger
    Calella, Anna M.
    Peltz, Gerson
    Solomon, Benjamin J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (21): : 2018 - 2029
  • [50] Impact of alectinib on survival after crizotinib failure in ALK-positive NSCLC patients.
    Yoshida, Tatsuya
    Oya, Yuko
    Shimizu, Junichi
    Tanaka, Kosuke
    Horio, Yoshitsugu
    Hida, Toyoaki
    Yatabe, Yasushi
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345